About
Mammoth Biosciences is a cutting-edge genetic medicine company leveraging AI-assisted protein discovery, engineering, and novel CRISPR-Cas systems to advance in vivo gene editing. Co-founded with Jennifer Doudna—co-inventor of CRISPR—the company operates at the forefront of translating foundational CRISPR science into permanent, precision therapeutic cures for serious diseases. The platform is organized into three pillars: Therapeutics, which pursues in vivo CRISPR-based editing to deliver durable patient cures; Protein Discovery and Engineering, which discovers and engineers ultracompact and novel CRISPR-Cas systems (such as NanoCas) capable of overcoming critical delivery barriers; and Diagnostics, which provides a revolutionary CRISPR-based molecular detection platform for limitless testing applications. Mammoth's NanoCas system represents a breakthrough ultracompact CRISPR editor capable of extrahepatic gene editing, demonstrated in non-human primates for skeletal muscle. The company has secured major partnerships, including a collaboration with Regeneron for next-generation CRISPR-based gene editing across multiple diseases. Targeted at biopharma enterprises, research institutions, and diagnostic developers, Mammoth Biosciences offers a robust platform for licensing and partnership. Its AI-informed protein engineering capabilities enable the systematic discovery of new editing enzymes, dramatically expanding the toolkit available for genetic medicine and precision diagnostics.
Key Features
- In Vivo Gene Editing Therapeutics: Develops permanent, precision CRISPR-based cures delivered directly inside the body, targeting serious and unmet diseases.
- AI-Assisted Protein Discovery & Engineering: Uses computational and AI-driven methods to discover and engineer novel CRISPR-Cas enzymes, including ultracompact systems like NanoCas for improved delivery.
- NanoCas Ultracompact CRISPR System: A first-of-its-kind efficient ultracompact extrahepatic gene editor demonstrated in non-human primates, enabling editing beyond the liver.
- CRISPR-Based Molecular Diagnostics: Provides a highly programmable, CRISPR-powered detection platform enabling rapid, accurate, and scalable molecular diagnostic applications.
- Enterprise Partnering & Licensing: Offers collaboration models with biopharma leaders like Regeneron to develop next-generation CRISPR-based gene editing solutions across multiple disease areas.
Use Cases
- Biopharma companies seeking to license novel CRISPR-Cas enzymes and ultracompact gene editing systems for therapeutic development
- Genetic medicine researchers exploring in vivo delivery solutions for extrahepatic tissues such as muscle, lung, or eye
- Diagnostic companies integrating CRISPR-based molecular detection into rapid testing workflows for infectious diseases or genetic conditions
- Biotech startups and enterprise R&D teams looking to partner on next-generation gene editing modalities beyond traditional CRISPR-Cas9
- Academic and translational research institutions studying novel protein engineering approaches and CRISPR system diversification
Pros
- World-Class Scientific Founding Team: Co-founded with Jennifer Doudna, CRISPR co-inventor and Nobel laureate, lending unmatched scientific credibility and deep IP.
- Breakthrough Ultracompact CRISPR Delivery: NanoCas overcomes one of the biggest hurdles in gene therapy—cargo size and delivery—by enabling extrahepatic in vivo editing.
- Broad Platform Applicability: Single platform spans therapeutics, protein discovery, and diagnostics, offering multiple commercial and partnership avenues.
- Strong Industry Partnerships: Collaborations with top-tier biopharma (e.g., Regeneron) validate the platform and accelerate pipeline development.
Cons
- Not a Consumer or SaaS AI Tool: Mammoth Biosciences is a biotech R&D company, not a software-as-a-service product, limiting direct accessibility for individual users or developers.
- Early-Stage Therapeutic Pipeline: Lead therapeutic candidates are in preclinical stages, so clinical validation and regulatory approval are still years away.
- Enterprise-Only Access: Partnering with Mammoth typically requires enterprise-level agreements, making it inaccessible to independent researchers or small organizations.
Frequently Asked Questions
What is Mammoth Biosciences?
Mammoth Biosciences is a genetic medicine company that develops novel CRISPR-Cas systems, AI-assisted protein discovery tools, in vivo gene editing therapeutics, and CRISPR-based molecular diagnostic platforms.
Who co-founded Mammoth Biosciences?
Mammoth Biosciences was co-founded by Jennifer Doudna, the Nobel Prize-winning co-inventor of CRISPR-Cas9, along with a team of scientists, engineers, and entrepreneurs.
What is NanoCas?
NanoCas is Mammoth's proprietary ultracompact CRISPR system—the first efficient extrahepatic gene editor of its kind—that has been shown to edit skeletal muscle in non-human primates using AAV delivery.
How can companies partner with Mammoth Biosciences?
Biopharma and biotech companies can pursue licensing agreements or research collaborations with Mammoth, as demonstrated by their partnership with Regeneron for multi-disease gene editing programs.
What diseases is Mammoth targeting?
Mammoth is focused on serious diseases with high unmet medical need, including genetic muscle diseases (e.g., MB-111 targeting skeletal muscle conditions), with additional programs across multiple therapeutic areas in collaboration with partners.
